Product nameAnti-Glucose Transporter GLUT1 antibody
See all Glucose Transporter GLUT1 primary antibodies
DescriptionRabbit polyclonal to Glucose Transporter GLUT1
Tested applicationsSuitable for: ICC/IF, IHC-FoFr, ICC, Immunomicroscopy, IP, WB, IHC-Fr, IHC-Pmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide conjugated to KLH, corresponding to amino acids 478-492 of Human Glucose Transporter GLUT1 (Peptide available as ab115830.)
- renal cell carcinoma lysate (see Abreview) human erythocyte membranes
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.60
Preservatives: 0.05% Sodium azide, 0.01% Thimerosal (merthiolate)
Constituents: 0.164% Sodium phosphate, 1.45% Sodium chloride, 1.5% BSA
Concentration information loading...
Our Abpromise guarantee covers the use of ab652 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use at an assay dependent concentration.|
|IHC-FoFr||Use at an assay dependent concentration.|
|Immunomicroscopy||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
|WB||1/500 - 1/1000. Detects a band of approximately 55 kDa. We would not recommend boiling due to the possible irreversible aggregation of glycose transporters. If samples are boiled it can prevent some of the protein from entering the gel or produce multimers which are often mistaken for background. Samples should be solubilized in standard SDS Laemmli buffer and maintained at room temperature before loading.|
|IHC-Fr||Use at an assay dependent concentration.|
|IHC-P||1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
FunctionFacilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses.
Tissue specificityExpressed at variable levels in many human tissues.
Involvement in diseaseDefects in SLC2A1 are the cause of glucose transporter type 1 deficiency syndrome (GLUT1DS) [MIM:606777]; also known as blood-brain barrier glucose transport defect. This disease causes a defect in glucose transport across the blood-brain barrier. It is characterized by infantile seizures, delayed development, and acquired microcephaly.
Defects in SLC2A1 are the cause of dystonia type 18 (DYT18) [MIM:612126]. DYT18 is an exercise-induced paroxysmal dystonia/dyskinesia. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT18 is characterized by attacks of involuntary movements triggered by certain stimuli such as sudden movement or prolonged exercise. In some patients involuntary exertion-induced dystonic, choreoathetotic, and ballistic movements may be associated with macrocytic hemolytic anemia.
Sequence similaritiesBelongs to the major facilitator superfamily. Sugar transporter (TC 2.A.1.1) family. Glucose transporter subfamily.
modificationsPhosphorylated upon DNA damage, probably by ATM or ATR.
Cellular localizationCell membrane. Melanosome. Localizes primarily at the cell surface (By similarity). Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
- Information by UniProt
- Choreoathetosis/spasticity episodic (paroxysmal choreoathetosis/spasticity) antibody
- CSE antibody
- DYT17 antibody
All lanes : Anti-Glucose Transporter GLUT1 antibody (ab652) at 1/1000 dilution
All lanes : 2 week old Mouse brain tissue lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat HRP-conjugate anti-rabbit at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Exposure time: 2 seconds
ICC/IF image of ab652 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab652, 1/1000 dilution) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
ab652 at 1/250 staining human renal carcinoma tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step was performed before incubation with the primary antibody for 45 minutes. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
ab652 staining Glucose Transporter GLUT1 in mouse liver tissue section by Immunohistochemistry (Frozen sections). Tissue samples were fixed with formaldehyde and permeabilized with 0.2% Triton X-100 before blocking with 2% BSA was performed for 30 minutes at 200C. The sample was incubated with primary antibody (1/200) for 9 hours at 40C. An Alexa Fluor®488-conjugated Goat polyclonal to rabbit IgG was used as secondary antibody at dilution at 1/200. DAPI was used to stain the cell nuclei (blue).
ab652 staining Glucose Transporter GLUT1 in rat bone marrow cells by Immunocytochemistry/ Immunofluorescence. The cells were formaldehyde fixed then blocked using 5% serum for 1 hour at 25°C. Samples were then incubated with primary antibody at 1/250 for 9 hours at 4°C. The secondary antibody used was a goat anti-rabbit IgG conjugated to Alexa Fluor® 488 (green) used at a 1/250 dilution. DAPI was used to stain the cell nuclei (blue).
ab652 has been referenced in 151 publications.
- Falcão-Tebas F et al. Four weeks of exercise early in life reprograms adult skeletal muscle insulin resistance caused by a paternal high-fat diet. J Physiol 597:121-136 (2019). PubMed: 30406963
- Sonehara NM et al. Melatonin regulates tumor aggressiveness under acidosis condition in breast cancer cell lines. Oncol Lett 17:1635-1645 (2019). PubMed: 30675223
- Lee CF et al. Targeting NAD+ Metabolism as Interventions for Mitochondrial Disease. Sci Rep 9:3073 (2019). PubMed: 30816177
- Barnoud T et al. Tumor cells containing the African-Centric S47 variant of TP53 show increased Warburg metabolism. Oncotarget 10:1217-1223 (2019). PubMed: 30838093
- Chen H et al. Increased glycolysis mediates Wnt7b-induced bone formation. FASEB J N/A:fj201900201RR (2019). PubMed: 30913395